<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="92880"><DrugName>LY-3079514</DrugName><DrugSynonyms><Name><Value>LY-3079514</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="1005" type="ciIndication"><TargetEntity id="4148" type="siCondition"></TargetEntity><TargetEntity id="1570" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1005">Unidentified indication</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><LastModificationDate>2017-06-07T15:08:23.000Z</LastModificationDate><ChangeDateLast>2017-06-09T00:00:00.000Z</ChangeDateLast><AddedDate>2014-09-24T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; was developing LY-3079514, as an iv and sc formulation, for the potential treatment of 	an undisclosed indication. In October 2014, a  phase I trial  was   initiated, which completed in June 2015 [&lt;ulink linkID="1596066" linkType="Reference"&gt;1596066&lt;/ulink&gt;]. However, no further development has been reported since this time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2014, a single-dose, dose-escalation, phase I trial (&lt;ulink linkID="211109" linkType="Protocol"&gt;NCT02242903&lt;/ulink&gt;; 15190, I7B-MC-DPAA) was expected to be initiated later that month in the US in healthy volunteers (n = 72). At that time, the trial was expected to complete in February 2015; in October 2014, the trial was initiated. The trial completed in June 2015 [&lt;ulink linkID="1596066" linkType="Reference"&gt;1596066&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-15T00:00:00.000Z</StatusDate><Source id="1596066" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-09T00:00:00.000Z</StatusDate><Source id="1596066" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>